Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Status:
Completed

Trial end date:
2020-08-26

Target enrollment:

Participant gender:

Summary

This study will assess the safety, tolerability, and efficacy of ABBV-3373 in participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) compared with adalimumab.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Treatments:

Adalimumab